Page last updated: 2024-11-12
dictyostatin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dictyostatin: a macrocyclic compound; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11353099 |
CHEMBL ID | 226880 |
SCHEMBL ID | 14094924 |
MeSH ID | M0445373 |
Synonyms (7)
Synonym |
---|
CHEMBL226880 |
dictyostatin |
SCHEMBL14094924 |
(3z,5e,7r,8s,10s,11z,13s,14r,15s,17s,20r,21s,22s)-22-[(2s,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one |
(3~{z},5~{e},7~{r},8~{s},10~{s},11~{z},13~{s},14~{r},15~{s},17~{s},20~{r},21~{s},22~{s})-22-[(2~{s},3~{z})-hexa-3,5-dien-2-yl]-7,13,15,17,21-pentamethyl-8,10,14,20-tetrakis(oxidanyl)-1-oxacyclodocosa-3,5,11-trien-2-one |
(-)-dictyostatin |
Q43297542 |
Research Excerpts
Overview
Dictyostatin (DCT, 1) is a complex, flexible polyketide macrolide that demonstrates potent microtubule-polymerization activity. It causes cells to accumulate in the G2/M phase of the cell cycle.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (36)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID294923 | Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Synthesis and biological evaluation of novel analogues of dictyostatin. |
AID772395 | Stabilization of microtubule in HEK293 cells assessed as increase in acetylated alpha-tubulin after 4 hrs by ELISA | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID417071 | Growth inhibition of human AsPC1 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
AID772392 | Fraction unbound in CD1 mouse plasma at 5 mg/kg, ip dministered as single dose | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID417074 | Growth inhibition of paclitaxel-resistant human NCI/ADR cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
AID772384 | Fraction unbound in CD1 mouse brain at 5 mg/kg, ip administered as single dose | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID294921 | Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Synthesis and biological evaluation of novel analogues of dictyostatin. |
AID772391 | Plasma concentration in CD1 mouse at 5 mg/kg, ip administered as single dose at 4 hrs | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID410180 | Cytotoxicity against taxol-resistant human NCI/ADR-RES cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23 | Total synthesis and biological evaluation of potent analogues of dictyostatin: modification of the C2-C6 dienoate region. |
AID772393 | Stabilization of microtubule in HEK293 cells assessed as increase in acetylated alpha-tubulin at 1to 10 nM after 4 hrs by ELISA | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID294924 | Cytotoxicity against human Taxol-adriamycin-resistant NCI cells after 72 hrs by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Synthesis and biological evaluation of novel analogues of dictyostatin. |
AID410177 | Cytotoxicity against taxol-sensitive human AsPC1 cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23 | Total synthesis and biological evaluation of potent analogues of dictyostatin: modification of the C2-C6 dienoate region. |
AID291081 | Displacement of [3H]paclitaxel from bovine brain tubulin at 4 uM | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. |
AID410178 | Cytotoxicity against taxol-sensitive human DLD1 cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23 | Total synthesis and biological evaluation of potent analogues of dictyostatin: modification of the C2-C6 dienoate region. |
AID417076 | Cell cycle arrest in human PANC1 cells assessed as accumulation at S phase at 100 nM after 24 hrs by flow cytometry | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
AID318809 | Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay | 2008 | Journal of natural products, Mar, Volume: 71, Issue:3 | Synthesis and biological evaluation of 10,11-dihydrodictyostatin, a potent analogue of the marine anticancer agent dictyostatin. |
AID318807 | Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay | 2008 | Journal of natural products, Mar, Volume: 71, Issue:3 | Synthesis and biological evaluation of 10,11-dihydrodictyostatin, a potent analogue of the marine anticancer agent dictyostatin. |
AID291078 | Growth inhibition of beta tubulin Phe270Val mutant expressing human 1A9/Ptx10 cells after 72 hrs | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. |
AID772386 | Drug uptake in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 4 hrs | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID291076 | Increase in cellular tubulin polymer mass in HeLa cells assessed as minimum detectable effective concentration after 21 hrs | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. |
AID291079 | Growth inhibition of beta tubulin A364T mutant expressing human 1A9/Ptx22 cells after 72 hrs | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. |
AID291080 | Inhibition of bovine brain tubulin polymerization at 10 uM relative to paclitaxel | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. |
AID772383 | Stabilization of microtubule brain in CD1 mouse assessed as increase in acetylated alpha-tubulin at 5 mg/kg, ip administered as single dose measured after 7 days relative to vehicle-treated control | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID291077 | Growth inhibition of human 1A9 cells after 72 hrs | 2007 | Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13 | Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. |
AID410179 | Cytotoxicity against taxol-sensitive human PANC1 cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23 | Total synthesis and biological evaluation of potent analogues of dictyostatin: modification of the C2-C6 dienoate region. |
AID772388 | Plasma concentration in CD1 mouse at 5 mg/kg, ip administered as single dose at 16 hrs | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID318808 | Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay | 2008 | Journal of natural products, Mar, Volume: 71, Issue:3 | Synthesis and biological evaluation of 10,11-dihydrodictyostatin, a potent analogue of the marine anticancer agent dictyostatin. |
AID417075 | Cell cycle arrest in human PANC1 cells assessed as accumulation at G1 phase at 100 nM after 24 hrs by flow cytometry | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
AID318810 | Cytotoxicity against taxol-resistant human NCI/ADR cells after 72 hrs by MTT assay | 2008 | Journal of natural products, Mar, Volume: 71, Issue:3 | Synthesis and biological evaluation of 10,11-dihydrodictyostatin, a potent analogue of the marine anticancer agent dictyostatin. |
AID772387 | Drug uptake in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 16 hrs | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID294922 | Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Synthesis and biological evaluation of novel analogues of dictyostatin. |
AID772390 | AUC (0.25 to 4 hrs) in CD1 mouse plasma at 5 mg/kg, ip administered as single dose at 4 hrs | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID417073 | Growth inhibition of human PANC1 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
AID772385 | AUC (0.5 to 16 hrs) in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 4 hrs | 2013 | ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. |
AID417072 | Growth inhibition of human DLD1 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
AID417077 | Cell cycle arrest in human PANC1 cells assessed as accumulation at G2/M phase at 100 nM after 24 hrs by flow cytometry | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Total synthesis and biological evaluation of novel C2-C6 region analogues of dictyostatin. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (41)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 31 (75.61) | 29.6817 |
2010's | 10 (24.39) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 18.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.19) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (12.20%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 36 (87.80%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |